News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) to End Stomach-Cancer Drug Development



6/12/2009 7:23:55 AM

Bookmark and Share

Reuters -- Drugmaker ImmunoGen Inc said it was discontinuing further internal development of its experimental gastric-cancer drug, IMGN242, citing its slow progress, sending the company's shares down as much as 12 percent.


Read at Reuters
Read at Business Wire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES